|
Why changing drug laws is a political problem, not a scientific one
The overarching goal of Australian drug policy is harm minimisation. One obvious way to minimise drug related harm is to prohibit its use.
www.brisbanetimes.com.au
Alexion Pharmaceuticals added to S&P 500 index
Standard & Poor's Indices said Monday that it is adding the stock of drug developer Alexion Pharmaceuticals Inc. to its S&P 500 index.
news.yahoo.com
Europe Markets: Banks, drug makers lift European stocks, Spain off
Most European stock markets partly recover from last week’s steep losses on Monday, though pressure remains on Spanish stocks as investors fret about the country’s banks and economic situation.
www.marketwatch.com
Research and Markets: Pediatric Non-Clinical Drug Testing: Principles, Requirements, and Practice
Research and Markets has announced the addition of John Wiley and Sons Ltd's new book "Pediatric Non-Clinical
finance.yahoo.com
FDA staff sends mixed message on J&J drug Xarelto
WASHINGTON (Reuters) - U.S. drug reviewers had mixed opinions about whether Johnson & Johnson blood thinner Xarelto reduced the risk of new heart attacks and strokes in people with heart problems, setting the stage for heated debate by outside experts later this week. Some U.S. Food and Drug Administration staff members raised doubts about how well the drug worked, given the high number of ...
news.yahoo.com
PRESS RELEASE: AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody ...
MorphoSys AG / AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody Therapeutics . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. ...
www.finanzen.net
Accord paves way for opposing groups to talk
AN INTERNATIONAL accord on illicit drug policy has opened the way for dialogue between opponents and supporters of decriminalisation in Australia.
www.smh.com.au
Drug Sponsors' Regulatory Experience Was Mixed During PDUFA IV, According to Tufts Center for the Study of Drug ...
BOSTON, MA-- - Drug sponsors experienced a mixed regulatory burden under the FDA Amendments Act, which was also the fourth iteration of the Prescription Drug User Fee Act , according to new research from ...
finance.yahoo.com
AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody Therapeutics
MorphoSys AG / AbD Serotec to Launch Panel of HuCAL Anti-Drug Antibodies Supporting the Development of Novel Antibody Therapeutics . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this …
www.wallstreet-online.de
Leaders criticised for lack of debate
THE eminent public health campaigner David Penington has condemned political leaders over their failure to engage in a debate on drug use reform.
www.smh.com.au
|
